Topic

IL-4/IL-13 Inhibitor

Dupilumab, IL-4 receptor alpha antagonists, IL-4/IL-13 pathway blockade, access, coverage, and formulary positioning across atopic and eosinophilic diseases.

3 articles·Lives underPricing & Access Specialty·Last updated 2026-07-16

Pricing & Access· July 16, 2026 · 23 min read

Atopic dermatitis systemic access: Dupixent, JAK inhibitors, and biologics

By Ran Chen#Immunology #IL-4/IL-13 Inhibitor #JAK Inhibitor

Pricing & Access· July 15, 2026 · 21 min read

COPD Access Landscape 2026: Inhaled Triple Therapy, Dupilumab, and Ensifentrine

By Ran Chen#Respiratory #Payer Criteria #Specialty Pharmacy

Pricing & Access· May 17, 2026 · 11 min read

Dupixent coverage guide: formulary, prior authorization, and patient assistance

By Ran Chen#Immunology #IL-4/IL-13 Inhibitor #Prior Authorization